Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.67 |
| ▸ | FLT3 | P36888 | 5/20 | 0.53 |
| ▸ | KIT | P10721 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822297 | 0.93 | MET (0.59) | MET | |
| SCHEMBL4814790 | 0.93 | MET (0.57) | METFLT3KDR | |
| SCHEMBL4820012 | 0.92 | MET (0.61) | METFLT3KDR | |
| SCHEMBL4819117 | 0.90 | MET (0.55) | METFLT3KDR | |
| SCHEMBL4819186 | 0.89 | MET (0.56) | METFLT3KITKDREGFR | |
| SCHEMBL4822621 | 0.89 | MET (0.60) | METFLT3KITKDRLCK | |
| SCHEMBL4821183 | 0.89 | MET (0.55) | METFLT3KITKDRLCK | |
| SCHEMBL4818065 | 0.89 | MET (0.55) | METFLT3KDR | |
| SCHEMBL4820160 | 0.88 | MET (0.53) | METFLT3NTRK1 | |
| SCHEMBL4814708 | 0.87 | MET (0.54) | METFLT3KITKDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MET 721/4885FLT3 126/4885KIT 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.